The successes of the phase III trials of combination therapy based on immune checkpoint blockade (ICB) (anti-PD-L1 with anti-VEGF in the IMbrave150 study and anti-PD-L1 with anti-CTLA-4 in the HIMALAYA study) have transformed in systemic therapy for HCC (8,9). This evidence concerns the gene VEGFA and hepatocellular carcinoma.